NCT06043323View on ClinicalTrials.gov

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 8, 2024

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2028

Conditions
Follicular Lymphoma
Interventions
DRUG

Axicabtagene Ciloleucel

Given by IV (vein)

DRUG

Cyclophosphamide

Given by IV (vein)

DRUG

Fludarabine phosphate

Given by IV (vein)

DRUG

Prednisone

Given by IV (vein)

DRUG

Diphenhydramine

Given by IV (vein)

DRUG

Acetaminophen

Given by IV (vein)

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER